• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by AN2 Therapeutics Inc.

    4/22/26 4:02:31 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANTX alert in real time by email
    DEFA14A 1 antx-defa14a-2025.htm DEFA14A DEFA14A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

    Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    AN2 Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     


     

    img221957288_0.jpg

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! AN2 Therapeutics, Inc. Annual Meeting of Stockholders Wednesday, June 3, 2026 8:00 AM, Pacific Time Residence Inn, 555 Glenwood Avenue, Menlo Park, California 94025 styleINA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 3, 2026 for Stockholders of Record as of April 15, 2026 To order paper materials, use one of the following methods. For a convenient way to view proxy materials, vote, and obtain directions to attend the meeting, go to www.proxydocs.com/ANTX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy materials, which include the Notice and Proxy Statement and Annual Report, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 22, 2026. Internet: www.investorelections.com/ANTX Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img221957288_1.jpg

    AN2 Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: "FOR" each of the nominees in Proposal 1 and "FOR" Proposal 2 PROPOSAL 1. To elect each of the following nominees as Class I directors until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. 1.01 Kabeer Aziz 1.02 Gilbert Lynn Marks, M.D. 1.03 Rob Readnour, Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: In their discretion, Eric Easom, Lucy Day, and Josh Eizen are authorized to vote upon such other business properly brought before the Annual Meeting or any adjournments or postponements thereof.


    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX

    DatePrice TargetRatingAnalyst
    8/9/2024In-line → Underperform
    Evercore ISI
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    2/12/2024$25.00 → $7.00Outperform → In-line
    Evercore ISI
    2/12/2024Outperform → Perform
    Oppenheimer
    2/12/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ANTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in th

    3/31/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

    Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 20

    3/17/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces $40 Million Private Placement Financing

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc

    3/9/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    SEC Filings

    View All

    SEC Form DEF 14A filed by AN2 Therapeutics Inc.

    DEF 14A - AN2 Therapeutics, Inc. (0001880438) (Filer)

    4/22/26 4:01:53 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by AN2 Therapeutics Inc.

    DEFA14A - AN2 Therapeutics, Inc. (0001880438) (Filer)

    4/22/26 4:02:31 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by AN2 Therapeutics Inc.

    EFFECT - AN2 Therapeutics, Inc. (0001880438) (Filer)

    4/21/26 12:15:15 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aziz Kabeer

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    4/10/26 8:58:10 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Marks Gilbert Lynn

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    4/10/26 8:53:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Martin Patricia A.

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    4/10/26 8:51:47 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    5/29/25 4:17:48 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Readnour Robin Shane bought $86,708 worth of shares (60,000 units at $1.45) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    12/10/24 8:46:19 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AN2 Therapeutics downgraded by Evercore ISI

    Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform

    8/9/24 8:39:40 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously

    8/9/24 7:16:36 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00

    7/3/24 7:25:34 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Leadership Updates

    Live Leadership Updates

    View All

    Brii Biosciences Provides Latest Clinical Development and Corporate Updates

    Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

    7/5/23 7:18:00 PM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

    AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a

    5/9/22 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Financials

    Live finance-specific insights

    View All

    AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all

    8/16/24 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

    Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi

    3/28/24 4:10:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

    Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

    3/22/24 7:00:00 AM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:29:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:16:45 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/13/24 4:25:27 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care